Forecasting for products that are early in clinical development is challenging
Uncertain future clinical performance and environmental risk factors (e.g., competitive, regulatory, pricing, and market access) combine to raise the level of difficulty in developing product forecasts. In these situations, rather than focusing on point forecast estimates, communicating the range of possible forecast outcomes and their likelihood provides a more useful foundation for decision-making. In this webinar we outline approaches for incorporating risk in early-stage forecasts.

New machine learning tools for quantifying clinical uncertainty
Primary research methods to fill information gaps for novel molecules and market situations
Strategies for effectively communicating forecast risk to internal stakeholders

Satish is the Founder and CEO of Viscadia, with a career spanning more than 25 years in the life sciences industry. Having held forecasting leadership roles in global life science companies such as Pfizer and Abbvie, Satish also has deep experience in market research, new product planning, and business development.
Click to learn more >Founder & CEO

Douglas “Doug” Willson, Ph.D., leads the forecasting and business strategy team in our Cambridge office. He has over 30 years of forecasting and quantitative market research experience within the life sciences industry.
Click to learn more >Principal